A Clinical Study on Anti-Hypertensive Effect and Safety of Candesartan Cilexetil (Atacand) in Mild to Moderate Hypertensive Patients
Korean Circulation Journal
;
: 937-943, 1999.
Artículo
en Coreano
| WPRIM
| ID: wpr-102859
ABSTRACT
BACKGROUND AND OBJECTIVES:
Candesartan cilexetil (Atacand ), a selective type I angiotensin II receptor blocker, has recently been introduced as a new antihypertensive agent. We evaluated its anti-hypertensive effect and safety in mild to moderate hypertensive patients. MATERIALS ANDMETHODS:
Candesartan cilexetil, 8 mg or 16 mg, was administered once a day over 8 weeks period in the patients with mild to moderate hypertension (25 male, 26 female, mean age 53.5+/-1.2 years). For safety evaluation, laboratory tests were performed before and after treatment with candesartan cilexetil. Changes in blood pressure, heart rate and electrocardiogram were also observed.RESULTS:
1) The mean blood pressures in the sitting position were systolic 164.1+/-2.1 mmHg and diastolic 106.3+/-0.8 mmHg before treatment, which were lowered to 135.4+/-2.0 mmHg and 89.1+/-1.1 mmHg, repectively after 8 weeks of treatment (p0.05). 4) Laboratory tests revealed no significant abnormality by the treatment with candesartan cilexetil. 5) Left ventricular hypertrophy by ECG criteria detected in 3 cases disappeared after treatment with candesartan cilexetil. 6) No significant side effects were observed during the treatment period.CONCLUSION:
Candesartan cilexetil, 8 mg or 16 mg, once a day is an effective and well tolerated antihypertensive treatment. It has a significant dose-dependent antihypertensive effect.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Presión Sanguínea
/
Receptores de Angiotensina
/
Hipertrofia Ventricular Izquierda
/
Electrocardiografía
/
Frecuencia Cardíaca
/
Hipertensión
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Korean Circulation Journal
Año:
1999
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS